1. Home
  2. YQ vs ACET Comparison

YQ vs ACET Comparison

Compare YQ & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YQ

17 Education & Technology Group Inc.

N/A

Current Price

$2.55

Market Cap

34.8M

Sector

Real Estate

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$2.49

Market Cap

28.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YQ
ACET
Founded
2012
1947
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.8M
28.0M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
YQ
ACET
Price
$2.55
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $29.00
AVG Volume (30 Days)
3.1K
★ 284.0K
Earning Date
12-08-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$274.52
N/A
Revenue Next Year
$29.79
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.68
$0.46
52 Week High
$5.25
$9.97

Technical Indicators

Market Signals
Indicator
YQ
ACET
Relative Strength Index (RSI) 37.29 15.61
Support Level $2.44 N/A
Resistance Level $2.63 $9.51
Average True Range (ATR) 0.23 0.26
MACD -0.01 0.08
Stochastic Oscillator 2.94 4.69

Price Performance

Historical Comparison
YQ
ACET

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: